Abstract

P1.03 Survival Benefit of Surgically Resected Occult N2 (C-N0,1 and P-N2) Non-Small-Cell Lung Cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Chemotherapy
Herbert M Pinedo ... Giuseppe Giaccone
The Lancet | VOL. 349
Herbert M Pinedo, et. al.Herbert M Pinedo ... Giuseppe Giaccone
01 May 1997
Con: The Case for Expanded Lung Cancer Research Support
Mark W Geraci ... Robert L Keith
American journal of respiratory and critical care medicine | VOL. 184
Mark W Geraci, et. al.Mark W Geraci ... Robert L Keith
01 Dec 2011
One size does not fit all: Nuances in postoperative N2 non–small cell lung cancer management
Tim J Kruser ... Malcolm M Decamp
The Journal of thoracic and cardiovascular surgery | VOL. 156
Tim J Kruser, et. al.Tim J Kruser ... Malcolm M Decamp
29 Mar 2018
FDA Approves Avastin in Combination with Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
-
Cancer Biology & Therapy | VOL. 5
--
14 Nov 2006
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report
Simone Rossi ... Francesco Gelsomino
Journal of Thoracic Oncology | VOL. -
Simone Rossi, et. al.Simone Rossi ... Francesco Gelsomino
24 Jun 2024
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
Ross A Soo ... Dao Van Tu
Journal of Thoracic Oncology | VOL. -
Ross A Soo, et. al.Ross A Soo ... Dao Van Tu
14 Jun 2024
Board of Directors
-
Journal of Thoracic Oncology | VOL. 19
--
01 Jun 2024
Finding One Treatment for All Advanced EGFR-positive NSCLC—An Infinite Task
Edyta Maria Urbanska
Journal of Thoracic Oncology | VOL. 19
Edyta Maria UrbanskaEdyta Maria Urbanska
01 Jun 2024
View more papers